Ningbo Dahongying Pharmaceutical Co. Ltd.

Primary Study Objectives To investigate the pharmacokinetic behavior of a test formulation of bumetanide tablets (1 mg, manufactured by Ningbo Dahongying Pharmaceutical Co., Ltd.) and a reference formulation of bumetanide tablets (Burinex®, 1 mg, licensed by Karo Pharma AB) in healthy Chinese volunteers after single oral administration, both on an empty stomach and after a meal, and to evaluate the bioequivalence of the two formulations after both fasting and a meal. Secondary Study Objectives To evaluate the safety of a test formulation (T) bumetanide tablets and a reference formulation (R) bumetanide tablets (Burinex®) after single oral administration, both on an empty stomach and after a meal, in healthy Chinese volunteers.

Primary objective: To observe the pharmacokinetic characteristics of a single oral dose of 20 mg (fasting/after meal) of the test preparation atorvastatin calcium tablets (specification: 20 mg/tablet, produced by Ningbo Dahongying Pharmaceutical Co., Ltd.) and the reference preparation atorvastatin calcium tablets (Lipitor®, specification: 20 mg/tablet, produced by Pfizer Pharmaceuticals Co., Ltd.) in healthy adult Chinese subjects, and to evaluate the bioequivalence of the two preparations in fasting and after meal conditions. Secondary objective: To observe the safety of a single oral dose of 20 mg (fasting/after meal) of the test preparation and the reference preparation in healthy adult Chinese subjects.

Main purpose: Using levoamlodipine besylate tablets (specification: 5 mg) of Ningbo Dahongying Pharmaceutical Co., Ltd. as the test preparation and amlodipine besylate tablets (specification: 10 mg) of Pfizer Pharmaceuticals Co., Ltd. as the reference preparation, according to the relevant provisions of the bioequivalence test, the bioequivalence of the two preparations in healthy subjects was investigated. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.